Literature DB >> 27644575

Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease.

Yuko Toyoda1, Masaki Hanibuchi, Jun Kishi, Hiroshi Kawano, Shun Morizumi, Seidai Sato, Mayo Kondo, Terumi Takikura, Toshifumi Tezuka, Hisatsugu Goto, Yasuhiko Nishioka.   

Abstract

Acute exacerbation (AE) of interstitial lung disease is reported to be developed in not only idiopathic pulmonary fibrosis but also connective tissue disease-associated interstitial pneumonia (CTD-IP). As the significance of AE of CTD-IP has not been so widely recognized, its clinical feature is not fully elucidated. In the present study, we investigated the incidence, clinical features and outcome of AE of CTD-IP. We retrospectively reviewed admitted cases in our department with medical record from 2011 to 2015. Among 155 patients with CTD-IP, 10 (6.5%) cases developed AE (6 rheumatoid arthritis, 2 polymyositis/dermatomyositis, 1 systemic lupus erythematosus, 1 Sjögren syndrome), and one died of AE within 30 days. Median survival time after the onset of AE was 169 days in all 10 patients. The treatment with immunosuppressant just before AE onset might improve the prognosis of AE. The median survival time after the onset of AE was significantly longer in patients showing good response to corticosteroid compared with those with poor response to corticosteroid (805 days and 45 days, respectively) (p <0.05), suggesting that there are some cases in CTD-IP, showing the good response to corticosteroid even when AE was complicated. J. Med. Invest. 63: 294-299, August, 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27644575     DOI: 10.2152/jmi.63.294

Source DB:  PubMed          Journal:  J Med Invest        ISSN: 1343-1420


  13 in total

1.  Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature.

Authors:  Andreina Manfredi; Marco Sebastiani; Stefania Cerri; Caterina Vacchi; Roberto Tonelli; Giovanni Della Casa; Giulia Cassone; Amelia Spinella; Pancaldi Fabrizio; Fabrizio Luppi; Carlo Salvarani
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

2.  A systematic review of the incidence, risk factors and prognosis of acute exacerbation of systemic autoimmune disease-associated interstitial lung disease.

Authors:  Hiroyuki Kamiya; Ogee Mer Panlaqui
Journal:  BMC Pulm Med       Date:  2021-05-05       Impact factor: 3.317

Review 3.  Characteristics and evaluation of acute exacerbations in chronic interstitial lung diseases.

Authors:  Corey D Kershaw; Kiran Batra; Jose R Torrealba; Lance S Terada
Journal:  Respir Med       Date:  2021-04-26       Impact factor: 4.582

4.  Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study.

Authors:  Mengshu Cao; Jian Sheng; Xiaohua Qiu; Dandan Wang; Dongmei Wang; Yang Wang; Yonglong Xiao; Hourong Cai
Journal:  BMC Pulm Med       Date:  2019-11-14       Impact factor: 3.317

5.  Prognostic differences among patients with idiopathic interstitial pneumonias with acute exacerbation of varying pathogenesis: a retrospective study.

Authors:  Motoyasu Kato; Tomoko Yamada; Shunichi Kataoka; Yuta Arai; Keita Miura; Yusuke Ochi; Hiroaki Ihara; Ryo Koyama; Shinichi Sasaki; Kazuhisa Takahashi
Journal:  Respir Res       Date:  2019-12-18

6.  Feasibility and Outcomes of a Standardized Management Protocol for Acute Exacerbation of Interstitial Lung Disease.

Authors:  Colin J Adams; Karan Chohan; Dmitry Rozenberg; John Kavanagh; Gerhard Greyling; Shane Shapera; Jolene H Fisher
Journal:  Lung       Date:  2021-08-04       Impact factor: 2.584

Review 7.  Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows.

Authors:  Giulia Cassone; Andreina Manfredi; Caterina Vacchi; Fabrizio Luppi; Francesca Coppi; Carlo Salvarani; Marco Sebastiani
Journal:  J Clin Med       Date:  2020-04-10       Impact factor: 4.241

8.  Selection of glucocorticoid-sensitive patients in interstitial lung disease secondary to connective tissue diseases population by radiomics.

Authors:  Ding-Yun Feng; Yu-Qi Zhou; Yan-Fang Xing; Chuang-Feng Li; Qing Lv; Jie Dong; Jie Qin; Yue-Fei Guo; Nan Jiang; Chencui Huang; Hai-Tao Hu; Xing-Hua Guo; Jie Chen; Liang-Hong Yin; Tian-Tuo Zhang; Xing Li
Journal:  Ther Clin Risk Manag       Date:  2018-10-10       Impact factor: 2.423

9.  Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis.

Authors:  Noriyuki Enomoto; Yoshiyuki Oyama; Yasunori Enomoto; Hideki Yasui; Masato Karayama; Masato Kono; Hironao Hozumi; Yuzo Suzuki; Kazuki Furuhashi; Tomoyuki Fujisawa; Naoki Inui; Yutaro Nakamura; Takafumi Suda
Journal:  Chron Respir Dis       Date:  2018-10-31       Impact factor: 2.444

10.  Acute Exacerbation of Interstitial Lung Disease in Adult Patients With Idiopathic Inflammatory Myopathies: A Retrospective Case-Control Study.

Authors:  Junyu Liang; Heng Cao; Yini Ke; Chuanyin Sun; Weiqian Chen; Jin Lin
Journal:  Front Med (Lausanne)       Date:  2020-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.